0001878313 2026-08-21 2026-08-21 0001878313 1 2026-08-21 2026-08-21 0001878313 2 2026-08-21 2026-08-21 0001878313 3 2026-08-21 2026-08-21 0001878313 4 2026-08-21 2026-08-21 0001878313 5 2026-08-21 2026-08-21 0001878313 6 2026-08-21 2026-08-21 0001878313 7 2026-08-21 2026-08-21 0001878313 8 2026-08-21 2026-08-21 0001878313 9 2026-08-21 2026-08-21 0001878313 10 2026-08-21 2026-08-21 0001878313 11 2026-08-21 2026-08-21 0001878313 12 2026-08-21 2026-08-21 0001878313 13 2026-08-21 2026-08-21 0001878313 14 2026-08-21 2026-08-21 0001878313 1 2026-08-21 2026-08-21 0001878313 2 2026-08-21 2026-08-21 iso4217:USD pure S-3 S-3 EX-FILING FEES 0001878313 MAIA Biotechnology, Inc. N/A 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 true false S-3 MAIA Biotechnology, Inc. Equity Common stock, $0.0001 par value true Equity Preferred Stock, $0.0001 par value true Debt Debt Securities true Other Warrants true Other Subscription Rights true Other Units true false Unallocated (Universal) Shelf true 150000000.00 0.0001381 20715.00 Equity Common stock, $0.001 par value true S-3 333-273984 2023-08-23 Equity Preferred stock, $0.001 par value true S-3 333-273984 2023-08-23 Debt Debt Securities true S-3 333-273984 2023-08-23 Other Warrants true S-3 333-273984 2023-08-23 Other Subscription Rights true S-3 333-273984 2023-08-23 Other Units true S-3 333-273984 2023-08-23 Unallocated (Universal) Shelf true 94010093.10 S-3 333-273984 2023-08-23 992.34 244010093.10 20715.00 0.00 10359.92 10355.08 In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover an indeterminate number of additional shares of Common Stock to be offered or issued from stock splits, stock dividends or similar transactions. Pursuant to Instruction 2.A.iii.b. of Item 16(b) of Form S-3, this information is not specified as to each class of securities to be registered. There is being registered hereby such indeterminate number of the securities of each identified class as may from time to time be issued at indeterminate prices. Securities registered hereunder may be sold separately, together or in units with other securities registered hereunder. The proposed maximum aggregate offering price has been estimated solely to calculate the registration fee in accordance with Rule 457(o) under the Securities Act. A total registration fee of $16,530.00 was previously paid in connection with the Registrant's registration statement on Form S-3 (File No. 333-273984) initially filed on August 15, 2023, or the Prior Registration Statement. The Prior Registration Statement is scheduled to expire on August 23, 2026, subject to Rule 415(a)(ii). $10,359.92 of the registration fee is being applied toward the registration fee for this registration statement in reliance on Rule 457(p), because $94,010,093.10 of unsold securities (and associated fees) are being moved from the Prior Registration Statement to this registration statement. Pursuant to Rule 457(p), the $10,359.92 registration fee previously paid by the Registrant relating to the unsold securities included on this registration statement will continue to be applied to such unsold securities. true MAIA Biotechnology Inc. S-3 333-273984 2023-08-15 10359.92 Unallocated (Universal) Shelf Unallocated (Universal) Shelf 94010093.10 true MAIA Biotechnology, Inc. S-3 333-273984 2023-08-15 10359.92 An aggregate of $992.34 of the amount of the registration fee was previously paid in connection with $25,000,000 of unissued securities registered under the Registrant's Prior Registration Statement. The Registrant is allowed to apply $992.34 toward the registration fee for this registration statement in reliance on Rule 457(p), because the $9,004,894.40 of unsold securities (and associated fees) are being moved from the Prior Registration Statement to this registration statement. Pursuant to Rule 457(p), the $992.34 registration fee previously paid by the Registrant relating to the unsold securities included on this registration statement will continue to be applied to such unsold securities.